The Distinct Roles of Sialyltransferases in Cancer Biology and Onco-Immunology

Aberrant glycosylation is a key feature of malignant transformation. Hypersialylation, the enhanced expression of sialic acid-terminated glycoconjugates on the cell surface, has been linked to immune evasion and metastatic spread, eventually by interaction with sialoglycan-binding lectins, including...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 799861
Main Authors Hugonnet, Marjolaine, Singh, Pushpita, Haas, Quentin, von Gunten, Stephan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.12.2021
Subjects
Animals
cancer
Glycosylation
Humans
Immunology
Isoenzymes
Neoplasms - enzymology
Neoplasms - immunology
Neoplasms - metabolism
Protein Processing, Post-Translational
Selectins - metabolism
sialic acid
Sialic Acid Binding Immunoglobulin-like Lectins - metabolism
Sialic Acids - metabolism
sialyltransferases
Sialyltransferases - metabolism
Substrate Specificity
tumor glycosylation
tumor immunology
cancer
tumor immunology
sialic acid
tumor glycosylation
sialyltransferases
Online AccessGet full text

Cover

More Information
Summary:Aberrant glycosylation is a key feature of malignant transformation. Hypersialylation, the enhanced expression of sialic acid-terminated glycoconjugates on the cell surface, has been linked to immune evasion and metastatic spread, eventually by interaction with sialoglycan-binding lectins, including Siglecs and selectins. The biosynthesis of tumor-associated sialoglycans involves sialyltransferases, which are differentially expressed in cancer cells. In this review article, we provide an overview of the twenty human sialyltransferases and their roles in cancer biology and immunity. A better understanding of the individual contribution of select sialyltransferases to the tumor sialome may lead to more personalized strategies for the treatment of cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Behjatolah Monzavi-Karbassi, University of Arkansas for Medical Sciences, United States; Valeria I. Segatori, Universidad Nacional de Quilmes (UNQ), Argentina; Vered Padler-Karavani, Tel Aviv University, Israel; Thomas Boltje, Radboud University Nijmegen, Netherlands
Edited by: Heinz Laubli, University Hospital of Basel, Switzerland
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.799861